RICHMOND, Va., May 30, 2002 (PRIMEZONE) -- Canadian Biotech companies will discuss prospects and strategies at the Canadian Biotech Stocks Forum on Thursday, June 6. This online Forum, free to investors, is accessible at www.informedinvestors.com from 9:00 a.m.-10:00 a.m. PST. Investors have the opportunity to hear directly from company executives and get their investment information straight from the source.
The Informed Investors Forum will have senior executives from Aderex Technologies (TSE:AHX), AlphaRx (OTCBB:ALRX), and Biomira, Inc. (Nasdaq:BIOM), speaking for approximately 30 minutes each with PowerPoint presentations. Investors are invited to email questions to executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
Adherex Technologies Inc. is a Canadian publicly traded biotechnology corporation. It has a platform technology that includes a promising new way to treat cancer. Adherex's Phase I human trials of Exherin, its potentially ground-breaking therapy for arresting the growth of cancer tumors by cutting off its blood supply, is expected to begin before the end of the year, assuming regulatory approval is granted. The initial protocol for the Phase I trial has been written and a meeting is scheduled with Health Canada July 9th to discuss it. The company has arranged for the manufacturing of clinical test batches of Exherin and is in the process of finalizing the site for the trial.
AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. Its broad product pipeline consists of carefully selected, currently marketed drugs. However, AlphaRx offers a stronger commercial potential by applying its own superior proprietary drug delivery technology, which greatly increases medical benefits over existing products.
Biomira Inc. is a biotechnology company applying its leading technology in immunotherapy and organic chemistry for the development of cancer therapeutics. They recently reviewed plans for the Company's Phase III THERATOPE(r) vaccine analyses for metastatic breast cancer as well as other developments. "This year marks an important time in our Company's history as we may have the first glimpse of clinical data from the key THERATOPE(r) vaccine trial. The strength of the powering of our THERATOPE(r) vaccine Phase III clinical trial is on the final analysis, likely to commence in late 2003. However, the trial is designed with an interim analysis, which is event driven and is expected to commence in the third quarter of 2002," said Alex McPherson, MD, Ph.D., President and CEO of Biomira. "We are confident that we have designed a well-controlled and extensive trial, which should yield robust data and we are hopeful of a positive outcome at either the final or interim analysis. We believe the strong trial design is one of the factors that makes our company stand apart in the biotechnology industry."
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink family of companies serving self-reliant investors.
About WILink: Since 1992, WILink (www.worldinvestorlink.com) has opened information channels between public companies and potential investors. This year World Investor Link will make more than 5 million investor introductions to over 4,600 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and webcast investor events and company financial reports through WILink's relationships with over 204 leading financial media channels including The Wall Street Journal, Financial Times, Barron's and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions.
WILink, Inc., a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange), began operations in Richmond, Va. in 1993.